Hepatitis B immunoglobulin immunoprophylaxis for hepatitis B: High, low, or no dose?1

Abstract

Key Points 1. Transplantation for HBV-related HCC is increasing in the West, whilst HBV-relate liver failure is decreasing. 2. Combination lamivudine plus HBIG reduces the risk of HBV recurrence to less than 5%. 3. Low-dose IM HBIG ihas similar efficacy and better cost effectiveness than high-dose IV HBIG when combined with oral nucleos(t)ide therapy. 4. HBIG may be discontinued in low risk recipients (undetectable HBV DNA prior to transplant). 5. Combination of new potent antivirals without cross resistance may minimise the future need for post-operative HBIG. Liver Transpl 16:S36-S39, 2010. © 2010 AASLD.